File Download
Supplementary

Book Chapter: Adiponectin-based Therapeutics in Cancer Treatment

TitleAdiponectin-based Therapeutics in Cancer Treatment
Authors
Issue Date2017
PublisherBentham Science Publishers
Citation
Adiponectin-based Therapeutics in Cancer Treatment. In Atta-ur-Rahman, RFS (Ed.), Frontiers in Clinical Drug Research - Anti-Cancer Agents, v. 4, p. 274-313. Shariqah, United Arab Emirates: Bentham Science Publishers, 2017 How to Cite?
AbstractAdiponectin is an adipokine exclusively produced from adipocytes and exerts potent growth inhibitory activity in a wide range of cancer cells. Decreased expression and/or function of adiponectin are associated with increased risks and aggressive development of cancers with poor prognoses. To restore the expression level of endogenous adiponectin and to activate its functional pathways represent promising strategies for the prevention and treatment of cancer, especially in obese patients. However, the development of recombinant adiponectin as a therapeutic agent has been hampered by the complexity of its structures and the highly diversified functionality of this magic molecule. Here, the application of different adiponectin-based prophylactics and therapeutics in cancer treatment will be thoroughly reviewed and scrutinized.
Persistent Identifierhttp://hdl.handle.net/10722/248936
ISBN

 

DC FieldValueLanguage
dc.contributor.authorLi, D-
dc.contributor.authorCao, H-
dc.contributor.authorChen, J-
dc.contributor.authorLiu, M-
dc.contributor.authorWang, Y-
dc.date.accessioned2017-10-18T08:50:44Z-
dc.date.available2017-10-18T08:50:44Z-
dc.date.issued2017-
dc.identifier.citationAdiponectin-based Therapeutics in Cancer Treatment. In Atta-ur-Rahman, RFS (Ed.), Frontiers in Clinical Drug Research - Anti-Cancer Agents, v. 4, p. 274-313. Shariqah, United Arab Emirates: Bentham Science Publishers, 2017-
dc.identifier.isbn9781681084817-
dc.identifier.urihttp://hdl.handle.net/10722/248936-
dc.description.abstractAdiponectin is an adipokine exclusively produced from adipocytes and exerts potent growth inhibitory activity in a wide range of cancer cells. Decreased expression and/or function of adiponectin are associated with increased risks and aggressive development of cancers with poor prognoses. To restore the expression level of endogenous adiponectin and to activate its functional pathways represent promising strategies for the prevention and treatment of cancer, especially in obese patients. However, the development of recombinant adiponectin as a therapeutic agent has been hampered by the complexity of its structures and the highly diversified functionality of this magic molecule. Here, the application of different adiponectin-based prophylactics and therapeutics in cancer treatment will be thoroughly reviewed and scrutinized.-
dc.languageeng-
dc.publisherBentham Science Publishers-
dc.relation.ispartofFrontiers in Clinical Drug Research - Anti-Cancer Agents-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.titleAdiponectin-based Therapeutics in Cancer Treatment-
dc.typeBook_Chapter-
dc.identifier.emailWang, Y: yuwanghk@hku.hk-
dc.identifier.authorityWang, Y=rp00239-
dc.description.naturepublished_or_final_version-
dc.identifier.hkuros281070-
dc.identifier.volume4-
dc.identifier.spage274-
dc.identifier.epage313-
dc.publisher.placeShariqah, United Arab Emirates-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats